Results for Financial Results for Quarter and Financial Year ended March 31, 2026
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 03 Jun 2026, 07:05 PM IST · BSE ID: 9b1623ab-21d9-48c7-9882-8da2182045c7
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a net loss of -5843.31 Rs. Thousands for the latest quarter and -41590.82 Rs. Thousands for the full financial year.
🤖 AI Summary
- Parmax Pharma reported a net loss of -5843.31 Rs. Thousands for the quarter ended March 31, 2026.
- Total income for Q4 FY26 stood at 33385.81 Rs. Thousands, with revenue from operations at 33127.07 Rs. Thousands.
- For the full financial year ended March 31, 2026, net loss was -41590.82 Rs. Thousands.
- Full year FY26 total revenue from operations was 121115.93 Rs. Thousands, compared to 282039.58 Rs. Thousands in FY25.
- Basic earnings per share for Q4 FY26 was -1.56 Rs. per share, and -11.12 Rs. per share for FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (FY26)
121115.93 Rs. Thousands
Revenue from operations (FY25)
282039.58 Rs. Thousands
Net Profit / (Loss) for FY26
-41590.82 Rs. Thousands
Net Profit / (Loss) for FY25
-20940.10 Rs. Thousands
Basic EPS (FY26)
-11.12 Rs.
Total Equity (as at 31.03.2026)
-61477.52 Rs. Thousands
Total Non-Current Liabilities (as at 31.03.2026)
115182.41 Rs. Thousands
🏢 How This Affects the Company
The company's revenue from operations decreased to 121115.93 Rs. Thousands in FY26 from 282039.58 Rs. Thousands in FY25, indicating a significant reduction in sales volume or pricing.
Parmax Pharma recorded a net loss of -41590.82 Rs. Thousands for FY26, widening from a net loss of -20940.10 Rs. Thousands in FY25, impacting profitability. Total Equity decreased to -61477.52 Rs. Thousands as of March 31, 2026, from -19886.7 Rs. Thousands as of March 31, 2025.
The company did not charge depreciation on the cleanroom plant and effluent treatment plant during FY26, which may affect asset valuation and future operational costs.
Increased Non-current borrowings to 115182.41 Rs. Thousands as of March 31, 2026, from 77035.61 Rs. Thousands as of March 31, 2025, alongside significant losses, indicates heightened financial leverage risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the full year net loss of -41590.82 Rs. Thousands for FY26, resulting in a basic EPS of -11.12 Rs. per share for continuing operations.
🔍
Management Signal
The declaration of an unmodified audit opinion on the financial results indicates management's adherence to reporting standards for the disclosed performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor for any changes in revenue and loss trends.
Company disclosures regarding non-charging of depreciation for cleanroom plant and ETP.
Updates on the insurance claim lodged by the company.
HIGH RISK
Significant and increasing net losses, coupled with declining revenue and negative equity, indicate substantial financial risk.
💡 Investor Takeaway
Parmax Pharma reported a full year FY26 net loss of -41590.82 Rs. Thousands, a significant increase from the -20940.10 Rs. Thousands loss in FY25. Revenue from operations for FY26 decreased to 121115.93 Rs. Thousands from 282039.58 Rs. Thousands in FY25. The company's basic EPS for FY26 was -11.12 Rs. per share.
⚖️ Strengths & Concerns
⚠️ Concerns
- Net loss for FY26 widened to -41590.82 Rs. Thousands, compared to -20940.10 Rs. Thousands in FY25.
- Revenue from operations for FY26 decreased to 121115.93 Rs. Thousands from 282039.58 Rs. Thousands in FY25.
📅 Company Track Record
Parmax Pharma previously reported a net loss of -5843.31 Rs. Thousands for Q4 FY26 in an earlier filing on June 03, 2026, ahead of this detailed financial results disclosure. The Board meeting to approve these audited results was initially scheduled for May 30, 2026, and later rescheduled.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Parmax Pharma's net loss for the quarter ended March 31, 2026?
Parmax Pharma reported a net loss of -5843.31 Rs. Thousands for the quarter ended March 31, 2026.
What was Parmax Pharma's total revenue from operations for the financial year ended March 31, 2026?
The total revenue from operations for Parmax Pharma for the financial year ended March 31, 2026, was 121115.93 Rs. Thousands.
What was Parmax Pharma's net profit/loss for the full financial year ended March 31, 2026?
Parmax Pharma recorded a net loss of -41590.82 Rs. Thousands for the full financial year ended March 31, 2026.
What was Parmax Pharma's basic earnings per share for FY26?
Parmax Pharma's basic earnings per share for the financial year ended March 31, 2026, was -11.12 Rs. per share.
What was Parmax Pharma's Total Equity as of March 31, 2026?
As of March 31, 2026, Parmax Pharma's Total Equity stood at -61477.52 Rs. Thousands.
Questions based on this BSE filing only. For information purposes.